CDK4 and neoplasm: In mammary fat pad xenografts, both CDK4/6 and TROJAN inhibition exhibited significant tumor growth reduction, whereas the combination of CDK4/6 and TROJAN inhibition further reduced tumor growth (Fig. 2g-h).